AU2018346960A1 - Conformational epitopes in respiratory syncytial virus G protein central conserved region - Google Patents

Conformational epitopes in respiratory syncytial virus G protein central conserved region Download PDF

Info

Publication number
AU2018346960A1
AU2018346960A1 AU2018346960A AU2018346960A AU2018346960A1 AU 2018346960 A1 AU2018346960 A1 AU 2018346960A1 AU 2018346960 A AU2018346960 A AU 2018346960A AU 2018346960 A AU2018346960 A AU 2018346960A AU 2018346960 A1 AU2018346960 A1 AU 2018346960A1
Authority
AU
Australia
Prior art keywords
seq
rsv
peptide
mutant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018346960A
Other languages
English (en)
Inventor
Rebecca DUBOIS
Stas FEDECHKIN
Lawrence M. Kauvar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
University of California San Diego UCSD
Original Assignee
Trellis Bioscience Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Trellis Bioscience Inc
Publication of AU2018346960A1 publication Critical patent/AU2018346960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18533—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018346960A 2017-10-13 2018-10-12 Conformational epitopes in respiratory syncytial virus G protein central conserved region Abandoned AU2018346960A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762572271P 2017-10-13 2017-10-13
US62/572,271 2017-10-13
US201762588022P 2017-11-17 2017-11-17
US62/588,022 2017-11-17
US201862633999P 2018-02-22 2018-02-22
US62/633,999 2018-02-22
PCT/US2018/055711 WO2019075400A1 (en) 2017-10-13 2018-10-12 CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G

Publications (1)

Publication Number Publication Date
AU2018346960A1 true AU2018346960A1 (en) 2020-05-28

Family

ID=66101661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018346960A Abandoned AU2018346960A1 (en) 2017-10-13 2018-10-12 Conformational epitopes in respiratory syncytial virus G protein central conserved region

Country Status (6)

Country Link
US (2) US11773143B2 (enExample)
EP (1) EP3694548A4 (enExample)
JP (1) JP7445895B2 (enExample)
AU (1) AU2018346960A1 (enExample)
CA (1) CA3079604A1 (enExample)
WO (1) WO2019075400A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534239A (ja) 2018-08-08 2021-12-09 トレリス・バイオサイエンス，エルエルシー Ｒｓｖの改善された受動的および能動的ワクチン
US12367329B1 (en) * 2024-06-06 2025-07-22 EvolutionaryScale, PBC Protein binder search
CN119479801A (zh) * 2024-11-11 2025-02-18 苏州系统医学研究所 一种针对囊膜病毒表面抗原稳定突变位点的数据预测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
ATE412666T1 (de) * 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
NZ585589A (en) * 2007-10-25 2012-07-27 Trellis Bioscience Inc Anti-rsv g protein antibodies
EP2590675B1 (en) * 2010-07-07 2018-08-29 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
EP3408284A4 (en) * 2016-01-28 2019-08-14 The Brigham and Women's Hospital, Inc. DETERMINATION OF AN ANTIBODY AGAINST A PATHOGEN

Also Published As

Publication number Publication date
US20240150414A1 (en) 2024-05-09
EP3694548A4 (en) 2021-10-20
US11773143B2 (en) 2023-10-03
US20190135876A1 (en) 2019-05-09
JP7445895B2 (ja) 2024-03-08
JP2020536934A (ja) 2020-12-17
CA3079604A1 (en) 2019-04-18
WO2019075400A1 (en) 2019-04-18
EP3694548A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
US20240150414A1 (en) Conformational epitopes in respiratory syncytial virus g protein central conserved region
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
ES2349348T3 (es) Anticuerpos neutralizantes de rsv de ultra alta afinidad.
CN103483421B (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
CN105669838B (zh) 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
US9902765B2 (en) Antibodies against chikungunya virus and uses thereof
WO2018022786A1 (en) Antibodies to zika virus and methods of use thereof
ES3012638T3 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
Naidoo et al. The potential of nanobodies for COVID-19 diagnostics and therapeutics
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
JP2021507717A (ja) 抗原結合性ポリペプチド
US20240358817A1 (en) Structures of langya virus fusion protein ectodomain and immunogenic compositions derived therefrom
US20250066455A1 (en) Neutralising antibodies and uses thereof
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
WO2023040834A1 (zh) 一株羊驼源纳米抗体及其应用
WO2022210830A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
US10766929B2 (en) De novo designed hemagglutinin binding proteins
US12246063B2 (en) Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
US20250179152A1 (en) Sars-cov-2 neutralizing synthetic proteins
Fedechkin Structures Of Respiratory Syncytial Virus G Antigen Bound To Broadly Neutralizing Antibodies For Vaccine And Therapeutic Design
Van Zant et al. SARS-CoV-2 spike protein binding ligands and its application in COVID-19 therapeutics
WO2024061188A1 (zh) 一种冠状病毒多价疫苗及其应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted